| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/30/2022 | 32.98% | Goldman Sachs | $13 → $2.5 | Maintains | Neutral |
| 11/22/2022 | — | Craig-Hallum | Downgrades | Buy → Hold | |
| 11/10/2022 | 165.96% | Morgan Stanley | $11 → $5 | Maintains | Overweight |
| 11/09/2022 | — | Canaccord Genuity | Downgrades | Buy → Hold | |
| 11/09/2022 | — | JP Morgan | Downgrades | Overweight → Underweight | |
| 10/11/2022 | 485.11% | Morgan Stanley | $12 → $11 | Maintains | Overweight |
| 09/07/2022 | 591.49% | Goldman Sachs | $15 → $13 | Maintains | Neutral |
| 08/12/2022 | 538.3% | Morgan Stanley | $11 → $12 | Maintains | Overweight |
| 05/12/2022 | 485.11% | Morgan Stanley | $18 → $11 | Maintains | Overweight |
| 03/21/2022 | 804.26% | Goldman Sachs | $19 → $17 | Maintains | Neutral |
| 03/15/2022 | 1495.74% | Craig-Hallum | → $30 | Initiates Coverage On | → Buy |
| 03/11/2022 | 857.45% | Morgan Stanley | $20 → $18 | Maintains | Overweight |
| 11/15/2021 | 963.83% | Morgan Stanley | → $20 | Reinstates | → Overweight |
| 07/01/2021 | 910.64% | Goldman Sachs | $20 → $19 | Downgrades | Buy → Neutral |
| 04/19/2021 | 910.64% | Morgan Stanley | $18 → $19 | Maintains | Overweight |
| 03/08/2021 | 1123.4% | Canaccord Genuity | → $23 | Initiates Coverage On | → Buy |
| 03/08/2021 | 857.45% | Morgan Stanley | → $18 | Initiates Coverage On | → Overweight |
| 03/08/2021 | 804.26% | JP Morgan | → $17 | Initiates Coverage On | → Overweight |
| 03/08/2021 | 910.64% | Goldman Sachs | → $19 | Initiates Coverage On | → Buy |
What is the target price for Bioventus (BVS)?
The latest price target for Bioventus (NASDAQ: BVS) was reported by Goldman Sachs on November 30, 2022. The analyst firm set a price target for $2.50 expecting BVS to rise to within 12 months (a possible 32.98% upside). 12 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Bioventus (BVS)?
The latest analyst rating for Bioventus (NASDAQ: BVS) was provided by Goldman Sachs, and Bioventus maintained their neutral rating.
When is the next analyst rating going to be posted or updated for Bioventus (BVS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bioventus, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bioventus was filed on November 30, 2022 so you should expect the next rating to be made available sometime around November 30, 2023.
Is the Analyst Rating Bioventus (BVS) correct?
While ratings are subjective and will change, the latest Bioventus (BVS) rating was a maintained with a price target of $13.00 to $2.50. The current price Bioventus (BVS) is trading at is $1.88, which is out of the analyst's predicted range.